Please login to the form below
HTA bodies
This page shows the latest HTA bodies news and features for those working in and with pharma, biotech and healthcare.
Nature's way
Not to belittle recent advances or the brilliance of my colleagues in that area, but health technology assessment (HTA) is both harder and more difficult than drug or device safety assessment ... But our health economic capabilities are not there yet. If
Latest news
-
NICE International relaunches, will offer advisory services
NICE has become one of the world’s most prominent and well-know health technology assessment (HTA) bodies since its inception in 1999. ... NICE International will build on the expertise of those within the organisation and draw on links with academic
-
Ursula von der Leyen nominated for EU President role
Among other issues it highlighted was the question of better co-ordination of advice between regulatory authorities and HTA bodies. ... EFPIA yesterday called for a ‘refreshed approach’ to the plans, including ensuring that HTA and reimbursement
-
Lynparza set for further expansion with EU approval in breast cancer
The data looks like a significant step forward in treatment, but remains relatively modest, and without overall survival data it is likely to face resistance from HTA bodies such as
-
NICE and Canadian counterpart to offer joint advice service
The two HTA agencies have many methodologies in common, which prompted the launch of the initiative. ... Michelle Mujoomdar (pictured below), Acting Vice President, Evidence Standards, CADTH said: “This exciting new international collaboration between
-
How to pay for very high cost, curative drugs? ICER and NICE put their heads together
Pearson said that without this work, HTA bodies risked over or undervaluing these potential cures, which could harm patient care and healthcare systems. ... The collaboration between the HTA bodies reflects similar moves in Europe, where groups of
More from news
Approximately 0 fully matching, plus 40 partially matching documents found.
Latest Intelligence
-
Market shaping demands behaviour change
In fact, a 2019 study conducted by the German HTA organisation IQWiG concluded that they deem two-thirds of new innovations reaching the market today offer limited or no additional value ... It is now used extensively in policy and healthcare, with
-
Market shaping for better healthcare decisions
In addition, many global HTA bodies are at capacity with the reviews they are being commissioned to undertake, making an expensive, involved and long process even lengthier.
-
Great expectations: the urgent need for common purpose in Alzheimer’s disease
The access landscape is further complicated because many health technology assessment (HTA) methodologies are currently not geared up to evaluate these treatments. ... Yet NICE and many other HTA bodies limit their assessment to the cost-effectiveness of
-
It started with a miss
Similarly, commercial teams need to drill down and understand HTA requirements within the disease category to ensure trials are designed to capture the necessary data for modelling. ... When drugs don’t receive HTA regulatory support in major markets,
-
Integrating patient reported outcomes into clinical trials
That disconnect is evident in drug reviews published by health technology assessment (HTA) bodies, such as the United Kingdom’s National Institute for Health and Care Excellence (NICE). ... HTA bodies are grappling with some of these limitations
More from intelligence
Approximately 0 fully matching, plus 28 partially matching documents found.
Latest from PMHub
-
Market Shaping for Better Healthcare Decisions
In addition, many global HTA bodies are at capacity with the reviews they are being commissioned to undertake, making an expensive, involved and long process even lengthier.
-
Real-world evidence: breaking boundaries in rare disease
patients. When it comes to rare disease, you need real-world evidence.”. However, we are just starting to understand the power of RWE and many stakeholders, including payers, HTA bodies and
-
Plugging knowledge gaps to demonstrate the benefits of new medicines
The use of consensus techniques was determined by searching appraisal documents and web sites of UK-based HTA bodies. ... The use of consensus techniques was reported in nine technology appraisals from the three different UK HTA bodies, with numbers
-
Value of Medicines
David Coleiro, Paula Lashley and John Grime take a look at how society values medicines, the role of health technology assessment (HTA) bodies like NICE, what value means when it comes
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Graduate Business Analyst, Healthcare Communications – Pharma/ S...
-
Highly competitive salary
- Editorial Team Leader, Medical Communications, Oxford
-
Competitive Salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
-
Head of Copy
-
£ competitive
- AstraZeneca's Enhertu receives FDA grant for priority review
- BioNTech and InstaDeep collaboration develops SARS-CoV-2 Early Warning System
- Why pharma must get smart in its approach to customer engagement
- Pfizer’s Cibinqo granted FDA approval for adults with moderate-to-severe atopic dermatitis
- Vir Biotech launches new research programme for HIV and malaria prevention
- AstraZeneca’s Imfinzi and tremelimumab show unprecedented survival rate in liver cancer patients
- Developing Innovative Digital Strategies to Engage Patients
- GSK appoint Tony Wood as chief scientific officer
- Sanofi and Regeneron’s Dupixent receives second positive phase 3 trial results
- Cervical Cancer Prevention Month
- AstraZeneca’s Imfinzi and tremelimumab show unprecedented survival rate in liver cancer patients
- Almirall and IRB Barcelona announce new research collaboration
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Why pharma must get smart in its approach to customer engagement
- Watson completes Actavis acquisition, will rebrand in 2013
- BioNTech and InstaDeep collaboration develops SARS-CoV-2 Early Warning System
- Pre-launch planning and DSLs – the new ways to create launch excellence in pharma
- Actelion complete Ceptaris purchase
PMHub
KVA Digital
KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...
Latest intelligence
- Cervical Cancer Prevention Month
- In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...
- 6 critical success factors for flawless execution of a rapid first commercial launch
- Annemarie Armstrong, Executive Vice President, US Head of Client Services, shares the key considerations for launching a first commercial product, particularly on a rapid timeline....
- Hybrid working: Insights and tips for success
- Porterhouse Medical has thrived by embracing a hybrid approach to work. Our article looks at hybrid working and provides some tips for success...
